Market-Leading Customer Experience Company Avaya Enters Next Chapter of Accelerated Growth and Innovation
Avaya Holdings Corp. (“Avaya” or the “Company”), a global leader in customer experience solutions, today announced that it has successfully completed its financial restructuring and emerged from the Chapter 11 process with a growth-oriented capital structure that includes approximately $650 million in liquidity and a net leverage ratio of less than 1x. This milestone completes a critical step in the Company’s business transformation.
Alan Masarek, Avaya’s Chief Executive Officer, said, “Today, we turn the page and enter a new future for Avaya, our people and our customers. We are excited to fully realize the hard work we’ve put into our business transformation. We are moving ahead with significant financial resources to accelerate investment in our portfolio as we continue delivering innovation without disruption to our customers. Our customers are at different stages of their cloud journey. They want to move at a pace that meets their business needs – and in a way that allows them to adopt advanced functionality without business disruption. Avaya’s new, streamlined product roadmap was intentionally designed to do just this, incorporating input from our customers about the capabilities most meaningful to them. At a time when innovation has never been more important to an organization’s success, we are proud to be an answer to our customers’ most pressing challenges.”
Avaya is focused on building on its iconic brand, global customer footprint and massive partner ecosystem to deliver innovation without disruption on a global scale. The Company’s product innovation investments will continue to focus on the Avaya Experience Platform, which enables organizations to enhance their customer experience capabilities across myriad communications channels. Since the start of the year, the Company has rolled out more than 150 new product features and enhancements across its portfolio and launched Avaya Enterprise Cloud, a dedicated instance of Avaya’s core contact center, collaboration and unified communications software solutions for large enterprises. Avaya remains poised to capitalize on its product development momentum and address the current and future needs of its customers.
Mr. Masarek continued, “We are also pleased to welcome a new Board of Directors with extensive industry and financial leadership experience that will help Avaya usher in a new era of growth and operational excellence. Our incoming Board members bring decades of relevant expertise, insights and skillsets to support Avaya as we invest in driving the next wave of innovation in enterprise communications and providing our customers and partners with true omnichannel customer experience solutions.”
The Avaya Board of Directors now comprises nine directors, including:
- Alan Masarek is an industry innovator with over 30 years of experience leading communications, information technology and business services companies.
- Patrick Bartels, Managing Member of Redan Advisors, LLC, brings over 20 years of experience driving value for stakeholders of private and public companies through governance, incentive alignment, management evaluation, finance, capital markets and M&A.
- Patrick Dennis, Chief Executive Officer of ExtraHop, brings nearly 25 years of experience leading high-growth public and private companies in the software and information technology industries, including as CEO of Alvaria and Guidance Software and in leadership roles at EMC and Oracle.
- Robert Kalsow-Ramos, Partner in Private Equity at Apollo Global Management, Inc., is an experienced investment professional with deep expertise in the technology and services sectors and a successful track record of working with management teams to drive growth, innovation and stakeholder value creation.
- Marylou Maco, most recently Executive Vice President, Worldwide Sales and Field Operations at Genesys, brings three decades of industry experience and expertise in driving revenue and expanding market share in enterprise software, cloud services and network computing for global organizations.
- Aaron Miller, Partner in Private Equity at Apollo Global Management, Inc. and Head of Apollo Portfolio Performance Solutions, brings three decades of operational expertise driving successful company transformations across sectors.
- Donald E. Morgan, III CFA, Chief Investment Officer, Managing Partner and Portfolio Manager at Brigade Capital Management, LP, co-founded the firm in 2006 and has been instrumental in driving the firm’s growth, which has approximately $26 billion in assets under management.
- Tod Nielsen, most recently President and Chief Executive Officer of TalkWalker, is an industry veteran with decades of leadership experience connecting customers to SaaS and software platforms, including in executive roles at Salesforce, VMWare, Heroku, Oracle and Microsoft.
- Jacqueline Woods, Chief Marketing Officer at Teradata, is a technology and marketing executive with a strong track record of leading corporate transformations and growing successful businesses by enriching customer experiences.
Mr. Masarek added, “I appreciate the strong support that our investors have demonstrated throughout this process, and I thank our customers, partners, team members and other stakeholders for their unwavering commitment and trust in Avaya.”
Advisors
Kirkland & Ellis LLP served as legal counsel to Avaya, Evercore Group L.L.C. served as financial advisor and AlixPartners, LLP served as restructuring advisor.
Akin Gump Strauss Hauer & Feld LLP, Centerview Partners LLC and Alvarez & Marsal LLP served as legal counsel, investment banker and financial advisor, respectively, to an ad hoc group of Avaya’s first lien lenders. Paul, Weiss, Rifkind, Wharton & Garrison LLP served as legal counsel and FTI Consulting, Inc. served as financial advisor to an ad hoc group of Avaya’s first lien lenders. Debevoise & Plimpton LLP served as legal counsel to certain holders of Avaya’s secured exchangeable notes.
About Avaya
Businesses are built by the experiences they provide, and every day, millions of those experiences are delivered by Avaya Holdings Corp. Avaya is shaping the future of customer experiences, with innovation and partnerships that deliver game-changing business benefits. Our communications solutions power immersive, personalized, and memorable customer experiences to help organizations achieve their strategic ambitions and desired outcomes. Together, we are committed to helping grow your business by delivering Experiences That Matter. Learn more at http://www.avaya.com.
Cautionary Statement Regarding Forward-Looking Information
Certain statements discussed in this release as well as in other reports, materials and oral statements that the Company releases from time to time to the public constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Generally, words such as “anticipate,” “estimate,” “expect,” “could,” “intend,” “believe,” “plan,” “target,” “forecast” and similar expressions or the negative thereof are intended to identify forward-looking statements. Such forward-looking statements reflect management’s current expectations, strategic objectives, business prospects, anticipated economic performance and financial condition and other similar matters. Forward-looking statements are inherently uncertain and subject to a variety of assumptions, risks and uncertainties that could cause actual results to differ materially from those anticipated or expected by the management of the Company. Such factors include, but are not limited to: the Company’s ability to maintain relationships with suppliers, customers, employees and other third parties and regulatory authorities; market opportunities may not develop for the Company’s solutions and services in ways that the Company anticipates and the Company may not succeed in developing new innovative solutions and services to keep pace with rapidly changing technology, evolving industry standards and customer preferences; the impact and timing of any cost-savings measures and related local law requirements in various jurisdictions; the effectiveness of the Company’s internal control over financial reporting and disclosure controls and procedures, and the potential for additional material weaknesses in the Company’s internal controls over financial reporting or other potential weaknesses of which the Company is not currently aware or which have not been detected; and the impact of litigation and regulatory proceedings. These statements are not guarantees of future performance and actual events or results may differ significantly from these statements. Actual events or results are subject to significant known and unknown risks, uncertainties and other factors, many of which are beyond the Company’s control. It should be understood that it is not possible to predict or identify all such factors. Given these risks, investors and analysts should not place undue reliance on forward-looking statements. Forward-looking statements speak only as of the date of the document in which they are made. The Company disclaims any obligation or undertaking to provide any updates or revisions to any forward-looking statement as a result of new information, future events or otherwise, except as required by law. These statements constitute the Company’s cautionary statements under the PSLRA.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230430005027/en/
Contact information
Media Inquiries
Avaya Media Relations
CorpCommsTeam@avaya.com
Investor Inquiries
Tyler Chambers
Investors@avaya.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma19.10.2025 20:30:00 EEST | Press release
Incyte (Nasdaq:INCY) announced the first clinical data evaluating its TGFβR2×PD-1 bispecific antibody (INCA33890) for patients with microsatellite stable (MSS) colorectal cancer; and its potent, selective and orally bioavailable KRAS G12D inhibitor (INCB161734) for patients with KRAS G12D mutations, specifically pancreatic ductal adenocarcinoma (PDAC). The data were featured in two oral sessions (Investigational immunotherapy; Abstract #1522MO and Developmental therapeutics; Abstract #916O, respectively) at the European Society of Medical Oncology (ESMO) Congress 2025. “The proof-of-concept data highlight the potential of INCA33890 and INCB161734 to address significant medical needs in patients with advanced solid tumors, including MSS colorectal cancer and PDAC,” said Pablo J. Cagnoni, M.D., President and Head of Research and Development, Incyte. “These results, including the favorable safety profiles as monotherapies, support continued clinical development. We look forward to explori
Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment19.10.2025 12:15:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical Oncology (ESMO) 2025 Annual Meeting. The data demonstrated a progression-free survival (PFS) benefit for patients who experienced disease progression while on or after taking a PARP inhibitor (PARPi), a patient population with particularly poor prognosis. The presentation slides can be found here. The company also announced expansion of the Phase 2 BELLA trial in a poster session at ESMO, found here. New relacorilant data presented at ESMO demonstrated a consistent benefit in PARPi subgroups to overcome chemotherapy resistance. Relaco
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA ™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 14:00:00 EEST | Press release
Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the durable benefit that vimseltinib can offer patients.” Summary of Data and Findings from the 2-year results of the MOTION Phase
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 17:09:00 EEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 17:00:00 EEST | Press release
Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the study increased considerably to 76.2% (95% CI: 63.8, 86.0) by blinded independent review committee (BICR) per RECIST v1.1, from 54% at Week 25. The study also showed continued clinically meaningful improvements in key secondary endpoints related to patient outcomes such as pain and function. The safety profile was consistent with previously reported data. The results are being presented today in the Sarcoma mini-oral session at the European Society for Medical
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom